Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors.
Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve more »
OPKO Health Supports National Prostate Cancer Council Legislation more »
OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.